Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model. (1st November 2016)

• Record Type: Journal Article
• Authors: Yeo, Dannel; Huynh, Nhi; Beutler, John A.; Baldwin, Graham S.; He, Hong; Nikfarjam, Mehrdad
• Is Part Of: Journal of investigative surgery. Volume 29:Number 6(2016:Dec.)
• Page Start: 366
• Page End: 372
• Publication Date: 2016-11-01
• Subjects: glaucarubinone -- gemcitabine -- pancreatic cancer -- survival; Surgery -- Research -- Periodicals; Research; Surgery; Surgical Procedures, Operative; 617.075
• DOI: 10.3109/08941939.2016.1160167
• Languages: English
• ISSNs: 0894-1939

Abstract

ABSTRACT: Background : Pancreatic cancer continues to have a poor survival rate with an urgent need for improved treatments. Glaucarubinone, a natural product first isolated from the seeds of the tree Simarouba glauca, has recently been recognized as having anti-cancer properties that may be particularly applicable to pancreatic cancer. Methods : The effect of glaucarubinone on the growth and migration of murine pancreatic cancer cells was assessed by 3 H-thymidine incorporation assay. The survival impact of glaucarubinone alone and in combination with gemcitabine chemotherapy was assessed using an immunocompetent orthotopic murine model of pancreatic cancer. Results : Glaucarubinone inhibited the growth of the murine pancreatic cancer cell lines LM-P and PAN02. Treatment with either glaucarubinone or gemcitabine reduced proliferation in vitro and the combination was synergistic. The combination treatment improved survival two-fold compared to gemcitabine treatment alone ( p = 0.046) in PAN02 cells. Conclusions : The synergistic inhibition by glaucarubinone and gemcitabine observed in vitro and the improved survival in vivo suggest that glaucarubinone may be a useful adjunct to current chemotherapy regimens.